Download Files:
Droxidopa
$90 – $430
Products Details
Product Description
– Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder)[1][2][3][4].
Web ID
– HY-13458
Storage Temperature
– Store at 4°C, do not freeze
Shipping
– Isolate blue ice and the product with bubble pack to avoid direct contact
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C9H11NO5
References
– [1]Horacio Kaufmann, et al. Droxidopa for neurogenic orthostatic hypotension. Neurology, 2014; 83(4).|[2]Dela Peña I, et al. Droxidopa alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats. Eur J Pharmacol. 2021 Feb 5;892:173826.|[3]Cao LF, et al. Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson’s Disease. Neural Plast. 2016;2016:6383240. |[4]Kaufmann H. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res. 2008 Mar;18 Suppl 1:19-24.
CAS Number
– 23651-95-8
Molecular Weight
– 213.19
Compound Purity
– 98.04
SMILES
– OC1=C(O)C=CC([C@@H](O)[C@@H](C(O)=O)N)=C1
Clinical Information
– Launched
Research Area
– Neurological Disease
Solubility
– DMSO : 1.8 mg/mL (ultrasonic;warming)|H2O : < 0.1 mg/mL
Target
– Adrenergic Receptor
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
